NVAX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
56.7M
-59.4%
139.5M
-5.2%
147.1M
+108.9%
70.4M
-70.6%
239.2M
Cost of Revenue
14.2M
-53.6%
30.7M
+38.9%
22.1M
+2.8%
21.5M
+40.3%
15.3M
Gross Profit
42.5M
-61.0%
108.8M
-13.0%
125.0M
+155.4%
48.9M
-78.1%
223.9M
Operating Expenses
97.4M
-21.6%
124.2M
+12.1%
110.8M
-51.2%
227.0M
+84.8%
122.8M
R&D
70.7M
-26.0%
95.5M
+25.8%
75.9M
-22.8%
98.3M
+24.0%
79.2M
SG&A
26.7M
-7.3%
28.8M
-15.7%
34.1M
+7.8%
31.7M
-27.4%
43.6M
Operating Income
-54906000
-255.8%
-15430000
-208.4%
14.2M
+108.0%
-178018000
-276.1%
101.1M
EBITDA
-51850000
-319.2%
-12368000
-161.3%
20.2M
+127.1%
-74395000
-168.5%
108.6M
Net Income
-53387000
-462.5%
-9491000
-154.2%
17.5M
+108.7%
-202379000
-290.0%
106.5M
EPS (Basic)
$-0.32
-433.3%
$-0.06
-154.5%
$0.11
+108.8%
$-1.25
-289.4%
$0.66
EPS (Diluted)
$-0.32
-433.3%
$-0.06
-160.0%
$0.10
+108.0%
$-1.25
-301.6%
$0.62
Shares (Diluted)
164.6M
+0.8%
163.3M
-6.8%
175.2M
+7.9%
162.4M
-8.4%
177.2M
Novavax (NVAX) โ€” Financials